Tripeptide KPV, via PepT1, prevents colitis-associated cancer development in mice
Background
The human intestinal peptide transporter 1, encoded by the hPepT1 gene, is normally expressed at low levels in the healthy colon but becomes significantly upregulated during inflammatory bowel disease (IBD). Chronic intestinal inflammation is a known major risk factor for developing colorectal cancer, a condition termed colitis-associated cancer (CAC). Given the link between inflammation and cancer, and the elevated presence of PepT1 in inflamed intestinal tissue, researchers hypothesized that this transporter might play a direct role in the progression from chronic colitis to malignancy. This study aimed to elucidate the specific function of PepT1 in CAC development and to explore its potential as a therapeutic target.
Study Design
To investigate the role of PepT1, researchers used three distinct murine models: wild-type (WT) mice, transgenic mice with intestinal overexpression of human hPepT1 (TG), and PepT1 knockout mice (PepT1-KO). Colitis-associated cancer (CAC) was chemically induced in all groups using an azoxymethane/dextran sulfate sodium (AOM/DSS) protocol. In a separate arm of the study, the anti-inflammatory tripeptide KPV (Lys-Pro-Val) was administered to both WT and PepT1-KO mice undergoing the AOM/DSS protocol to assess its therapeutic potential and dependence on the PepT1 transporter. Tumorigenesis was evaluated by measuring tumor number, size, and overall burden.
Results
Overexpression of hPepT1 in TG mice significantly worsened cancer outcomes compared to WT mice, resulting in larger tumor sizes and increased tumor burdens. Conversely, deleting the transporter in PepT1-KO mice led to a significant decrease in tumor number and size, as well as reduced intestinal inflammation. Analysis of human colonic biopsies confirmed these findings, revealing increased expression of PepT1 in patients with colorectal cancer. The therapeutic intervention with the tripeptide KPV was highly effective in WT mice, successfully preventing carcinogenesis.
However, when KPV was administered to PepT1-KO mice, it did not trigger any of the inhibitory effects on tumorigenesis, demonstrating that KPV's protective action is entirely dependent on its transport into cells by
PepT1.
Key Findings
- Overexpression of hPepT1 in mice led to larger tumor sizes and increased tumor burdens.
- Deletion of PepT1 (PepT1-KO) in mice significantly decreased tumor number, size, and intestinal inflammation.
- The anti-inflammatory tripeptide KPV was able to prevent carcinogenesis in wild-type mice.
- KPV's anti-tumorigenic effects were completely absent in PepT1-KO mice, proving its action is PepT1-dependent.
- Expression of PepT1 was found to be increased in human colorectal cancer patient biopsies.
Why It Matters
This study reveals a dual role for the PepT1 transporter: it's a promoter of colitis-associated cancer but also the necessary gateway for the anti-cancer effects of the peptide KPV. For individuals with IBD, elevated PepT1 levels could be a biomarker for increased cancer risk. The key takeaway is that therapeutic strategies could involve delivering anti-inflammatory peptides like KPV that are specifically taken up by PepT1, turning a pro-tumorigenic factor into a drug delivery channel. This suggests a targeted approach where the very mechanism driving the pathology is hijacked for treatment. Further research is needed to translate this PepT1-dependent KPV therapy into a viable protocol for preventing CAC in high-risk human populations.
kpv
pept1
colitis
colorectal cancer
inflammatory bowel disease
animal study
